secwatch.observer — SEC 8-K summary
======================================

Issuer:     Unicycive Therapeutics, Inc. (UNCY)
CIK:        0001766140
Form:       8-K
Filed at:   2024-06-20T23:59:59+00:00
Accession:  0001213900-24-054279
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Unicycive stockholders approve Nasdaq 20% issuance and share increase at annual meeting
--------------------------------------------------------------------------------

- All four director nominees elected: Dr. Shalabh Gupta, Dr. Sandeep Laumas, Dr. Gaurav Aggarwal, Dr. Saraswati Kenkare-Mitra.
- Appointment of Grassi & Co. CPAs as independent auditor for FY2024 ratified with 35,666,926 votes for.
- Nasdaq 20% Issuance Proposal approved with 26,794,427 votes for, 262,272 against.
- Authorized Share Increase Proposal approved with 34,150,333 votes for, 1,735,688 against.
- Second amendment and restatement of 2021 Omnibus Equity Incentive Plan approved with 26,540,959 votes for.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1766140/000121390024054279/0001213900-24-054279-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1766140/000121390024054279/ea0208180-8k_unicycive.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-054279

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer